TapImmune Launches Phase 2 Ovarian Cancer
Trial In Platinum-Sensitive Patients

Company-Sponsored Ovarian Cancer Trial
Has FDA Fast Track Designation

TapImmune, Inc. (NASDAQ: TPIV), a clinical- stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease today announced the opening of its Phase 2 company-sponsored ovarian cancer study in platinum-sensitive ovarian cancer patients. The company’s first three clinical sites have received regulatory and Investigational Review Board (IRB) approval to begin enrollment. The study will utilize TPIV 200, a T-cell therapy targeting the folate receptor alpha protein.
Read More »